TDMS Study 97006-02 Pathology Tables
NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59 FINAL#1 MICE Facility: Battelle Northwest Chemical CAS #: 108-10-1 Lock Date: 01/24/03 Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Include All a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 450 PPM 900 PPM 1800 PPM ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Moribund Sacrifice 10 9 6 9 Natural Death 5 3 5 3 Accidently Killed 1 Survivors Terminal Sacrifice 35 37 39 38 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Gallbladder (42) (44) (34) (40) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Intestine Large, Colon (48) (48) (49) (49) Intestine Large, Rectum (47) (48) (48) (49) Sarcoma, Metastatic, Skin 1 (2%) Intestine Large, Cecum (46) (48) (47) (49) Adenoma 1 (2%) Histiocytic Sarcoma 1 (2%) Intestine Small, Duodenum (47) (48) (47) (48) Adenoma 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Intestine Small, Jejunum (48) (47) (47) (48) Carcinoma 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Intestine Small, Ileum (48) (47) (47) (47) Histiocytic Sarcoma 1 (2%) Liver (50) (50) (50) (50) Hemangiosarcoma 1 (2%) 2 (4%) 1 (2%) Hepatoblastoma 1 (2%) Hepatocellular Carcinoma 3 (6%) 4 (8%) 4 (8%) 11 (22%) Hepatocellular Carcinoma, Multiple 3 (6%) 1 (2%) 2 (4%) Hepatocellular Adenoma 11 (22%) 10 (20%) 12 (24%) 9 (18%) Hepatocellular Adenoma, Multiple 2 (4%) 5 (10%) 8 (16%) 14 (28%) Hepatocholangiocarcinoma 1 (2%) 1 (2%) Histiocytic Sarcoma 2 (4%) 1 (2%) 5 (10%) Mesentery (11) (11) (13) (8) Hemangiosarcoma, Metastatic, Spleen 1 (8%) Hemangiosarcoma, Metastatic, Uterus 1 (8%) Page 2 NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 450 PPM 900 PPM 1800 PPM ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Hepatocholangiocarcinoma, Metastatic, Liver 1 (9%) Histiocytic Sarcoma 1 (13%) Sarcoma, Metastatic, Skin 1 (9%) Pancreas (50) (50) (49) (50) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%) Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%) Salivary Glands (50) (50) (50) (50) Carcinoma 1 (2%) Stomach, Forestomach (50) (50) (50) (50) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) Squamous Cell Carcinoma 1 (2%) Squamous Cell Papilloma 1 (2%) 3 (6%) Stomach, Glandular (49) (50) (48) (49) Tooth (1) (1) Histiocytic Sarcoma 1 (100%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (50) (50) (50) Hemangioma 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%) Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (50) (50) (50) (50) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%) Adrenal Medulla (50) (50) (49) (49) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) Pheochromocytoma Benign 2 (4%) 1 (2%) Islets, Pancreatic (50) (50) (49) (50) Carcinoma 1 (2%) Parathyroid Gland (28) (33) (30) (36) Adenoma 1 (3%) Pituitary Gland (50) (49) (48) (49) Histiocytic Sarcoma 1 (2%) 1 (2%) Page 3 NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 450 PPM 900 PPM 1800 PPM ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM - cont Pars Distalis, Adenoma 7 (14%) 9 (18%) 4 (8%) 6 (12%) Pars Intermedia, Adenoma 2 (4%) Thyroid Gland (50) (50) (49) (48) C-Cell, Adenoma 1 (2%) C-Cell, Carcinoma 1 (2%) Follicular Cell, Carcinoma 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM Peritoneum (2) (1) Hemangiosarcoma, Metastatic, Spleen 1 (50%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (50%) ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Clitoral Gland (45) (42) (41) (42) Hemangiosarcoma, Metastatic, Spleen 1 (2%) Ovary (49) (50) (48) (50) Cystadenoma 2 (4%) 1 (2%) 3 (6%) Histiocytic Sarcoma 2 (4%) 1 (2%) Uterus (50) (50) (49) (50) Carcinoma 1 (2%) 1 (2%) Hemangioma 1 (2%) Hemangiosarcoma 1 (2%) 2 (4%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) 3 (6%) Leiomyoma 1 (2%) 1 (2%) 1 (2%) Polyp Stromal 3 (6%) 2 (4%) 2 (4%) Polyp Stromal, Multiple 1 (2%) Sarcoma Stromal 1 (2%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (50) (50) (49) (50) Hemangiosarcoma, Metastatic, Spleen 1 (2%) 1 (2%) Histiocytic Sarcoma 3 (6%) 1 (2%) 1 (2%) Lymph Node (7) (3) (9) (5) Iliac, Histiocytic Sarcoma 1 (11%) Lumbar, Hemangiosarcoma 1 (11%) Lumbar, Histiocytic Sarcoma 1 (20%) Page 4 NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 450 PPM 900 PPM 1800 PPM ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM - cont Pancreatic, Hepatocholangiocarcinoma, Metastatic, Liver 1 (14%) Renal, Histiocytic Sarcoma 1 (14%) Lymph Node, Bronchial (44) (41) (39) (37) Hepatocholangiocarcinoma, Metastatic, Liver 2 (5%) 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (3%) Lymph Node, Mandibular (40) (42) (39) (38) Histiocytic Sarcoma 1 (3%) 1 (3%) Lymph Node, Mesenteric (50) (49) (49) (47) Hemangiosarcoma, Metastatic, Uterus 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%) Lymph Node, Mediastinal (46) (40) (38) (41) Carcinoma, Metastatic, Skin 1 (3%) Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%) 1 (3%) Histiocytic Sarcoma 2 (4%) 1 (2%) Spleen (50) (50) (49) (50) Hemangiosarcoma 1 (2%) 2 (4%) 2 (4%) 1 (2%) Hemangiosarcoma, Metastatic, Uterus 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%) Thymus (49) (47) (46) (46) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (50) (49) (50) (49) Carcinoma 1 (2%) 1 (2%) 1 (2%) 1 (2%) Skin (50) (50) (50) (50) Basal Cell Carcinoma 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Sarcoma 1 (2%) Subcutaneous Tissue, Fibrosarcoma 1 (2%) Subcutaneous Tissue, Fibrous Histiocytoma 2 (4%) 1 (2%) 1 (2%) Subcutaneous Tissue, Hemangioma 1 (2%) Subcutaneous Tissue, Hemangiosarcoma 1 (2%) Subcutaneous Tissue, Hemangiosarcoma, Metastatic, Spleen 1 (2%) Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) Subcutaneous Tissue, Liposarcoma 1 (2%) Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%) 3 (6%) Subcutaneous Tissue, Sarcoma, Multiple 1 (2%) Page 5 NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 450 PPM 900 PPM 1800 PPM ____________________________________________________________________________________________________________________________________ ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (50) (50) (50) (50) Histiocytic Sarcoma 1 (2%) Skeletal Muscle (1) (2) (3) (2) Carcinoma, Metastatic, Skin 1 (33%) Hemangiosarcoma, Metastatic, Spleen 1 (33%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%) 1 (50%) Histiocytic Sarcoma 1 (50%) Sarcoma 1 (33%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (50) (50) (50) Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Larynx (50) (50) (49) (50) Lung (50) (50) (50) (50) Alveolar/Bronchiolar Adenoma 3 (6%) 2 (4%) 1 (2%) 1 (2%) Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%) 1 (2%) Carcinoma, Metastatic, Skin 1 (2%) Carcinoma, Metastatic, Thyroid Gland 1 (2%) Hemangiosarcoma, Metastatic, Uterus 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 4 (8%) 1 (2%) 1 (2%) 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%) 1 (2%) Histiocytic Sarcoma 3 (6%) 1 (2%) 2 (4%) Nose (50) (50) (50) (49) Histiocytic Sarcoma 1 (2%) 1 (2%) Pleura (1) Carcinoma, Metastatic, Skin 1 (100%) Trachea (50) (50) (49) (50) ____________________________________________________________________________________________________________________________________ Page 6 NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 450 PPM 900 PPM 1800 PPM ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Eye (49) (48) (49) (50) Histiocytic Sarcoma 1 (2%) Harderian Gland (49) (49) (49) (50) Adenoma 6 (12%) 4 (8%) 2 (4%) 3 (6%) Carcinoma 1 (2%) 3 (6%) 2 (4%) 3 (6%) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (50) (50) (49) (50) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%) Histiocytic Sarcoma 2 (4%) 1 (2%) 3 (6%) Urinary Bladder (50) (50) (49) (50) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) *(50) Histiocytic Sarcoma 3 (6%) 1 (2%) 6 (12%) Lymphoma Malignant 13 (26%) 5 (10%) 11 (22%) 13 (26%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 7 NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 450 PPM 900 PPM 1800 PPM ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 42 40 40 42 Total Primary Neoplasms 75 60 73 84 Total Animals with Benign Neoplasms 29 29 30 33 Total Benign Neoplasms 37 37 39 40 Total Animals with Malignant Neoplasms 30 22 28 31 Total Malignant Neoplasms 38 23 34 44 Total Animals with Metastatic Neoplasms 9 3 4 1 Total Metastatic Neoplasm 27 19 11 2 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 8 NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 450 PPM 900 PPM 1800 PPM ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Moribund Sacrifice 9 6 12 9 Natural Death 1 2 3 4 Survivors Terminal Sacrifice 40 42 34 37 Natural Death 1 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Intestine Large, Cecum (49) (48) (47) (47) Intestine Small, Duodenum (49) (48) (45) (47) Adenoma 1 (2%) 1 (2%) 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Intestine Small, Jejunum (49) (48) (47) (47) Adenoma 1 (2%) Intestine Small, Ileum (49) (48) (48) (47) Carcinoma 1 (2%) 1 (2%) Liver (50) (50) (50) (50) Fibrous Histiocytoma, Metastatic, Skin 1 (2%) Hemangioma 1 (2%) Hemangiosarcoma 2 (4%) 1 (2%) 2 (4%) Hepatoblastoma 1 (2%) Hepatocellular Carcinoma 10 (20%) 11 (22%) 8 (16%) 7 (14%) Hepatocellular Carcinoma, Multiple 2 (4%) 1 (2%) 2 (4%) 2 (4%) Hepatocellular Adenoma 11 (22%) 14 (28%) 11 (22%) 19 (38%) Hepatocellular Adenoma, Multiple 6 (12%) 11 (22%) 12 (24%) 15 (30%) Hepatocholangiocarcinoma 5 (10%) 2 (4%) Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) Sarcoma, Metastatic, Bone 1 (2%) Mesentery (9) (3) (3) (4) Sarcoma, Metastatic, Salivary Glands 1 (25%) Pancreas (49) (50) (49) (50) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%) Histiocytic Sarcoma 1 (2%) Salivary Glands (50) (50) (48) (50) Sarcoma 1 (2%) Page 9 NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 450 PPM 900 PPM 1800 PPM ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Stomach, Forestomach (50) (49) (49) (50) Squamous Cell Carcinoma 1 (2%) Squamous Cell Papilloma 1 (2%) Stomach, Glandular (49) (49) (49) (49) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (50) (50) (50) Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%) 2 (4%) Sarcoma, Metastatic, Bone 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (50) (50) (49) (50) Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%) Sarcoma, Metastatic, Bone 1 (2%) Capsule, Adenoma 2 (4%) 1 (2%) 1 (2%) Adrenal Medulla (50) (50) (49) (50) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Ganglioneuroma 1 (2%) Pheochromocytoma Malignant 1 (2%) Islets, Pancreatic (49) (50) (49) (50) Adenoma 1 (2%) 1 (2%) 3 (6%) Pituitary Gland (50) (47) (48) (49) Astrocytoma Malignant, Metastatic, Brain 1 (2%) Histiocytic Sarcoma 1 (2%) Pars Distalis, Adenoma 1 (2%) Thyroid Gland (50) (49) (50) (50) Follicular Cell, Adenoma 1 (2%) Follicular Cell, Carcinoma 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ Page 10 NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 450 PPM 900 PPM 1800 PPM ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Epididymis (50) (50) (50) (50) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) Prostate (50) (49) (49) (50) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Sarcoma, Metastatic, Bone 1 (2%) Seminal Vesicle (50) (50) (49) (50) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Testes (50) (50) (50) (50) Interstitial Cell, Adenoma 2 (4%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (50) (49) (50) (49) Fibrous Histiocytoma, Metastatic, Skin 1 (2%) Hemangiosarcoma 1 (2%) Lymph Node (1) (2) Lymph Node, Bronchial (39) (35) (37) (39) Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%) 2 (6%) Sarcoma, Metastatic, Bone 1 (3%) Lymph Node, Mandibular (37) (36) (32) (34) Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%) Histiocytic Sarcoma 1 (3%) Sarcoma, Metastatic, Salivary Glands 1 (3%) Lymph Node, Mesenteric (49) (48) (48) (48) Sarcoma, Metastatic, Bone 1 (2%) Lymph Node, Mediastinal (42) (38) (36) (38) Hepatocholangiocarcinoma, Metastatic, Liver 3 (7%) 2 (5%) Sarcoma, Metastatic, Bone 1 (2%) Spleen (50) (50) (49) (49) Hemangiosarcoma 1 (2%) Histiocytic Sarcoma 1 (2%) Thymus (42) (44) (44) (47) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%) Sarcoma, Metastatic, Bone 1 (2%) Thymoma Malignant 1 (2%) ____________________________________________________________________________________________________________________________________ Page 11 NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 450 PPM 900 PPM 1800 PPM ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Skin (50) (50) (49) (50) Subcutaneous Tissue, Fibrosarcoma 1 (2%) Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%) 1 (2%) Subcutaneous Tissue, Hemangiosarcoma 1 (2%) Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) Subcutaneous Tissue, Sarcoma, Metastatic, Bone 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (50) (50) (50) (50) Sarcoma 1 (2%) Sarcoma, Metastatic, Bone 1 (2%) Skeletal Muscle (3) (2) Hepatocholangiocarcinoma, Metastatic, Liver 2 (67%) 2 (100%) Sarcoma, Metastatic, Bone 1 (33%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (50) (50) (50) Astrocytoma Malignant 1 (2%) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (50) (50) (50) (50) Alveolar/Bronchiolar Adenoma 8 (16%) 5 (10%) 1 (2%) 5 (10%) Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) Alveolar/Bronchiolar Carcinoma 5 (10%) 1 (2%) 3 (6%) 4 (8%) Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) Carcinoma, Metastatic, Harderian Gland 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 7 (14%) 5 (10%) 3 (6%) 5 (10%) Hepatocholangiocarcinoma, Metastatic, Liver 3 (6%) 2 (4%) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Bone 1 (2%) Sarcoma, Metastatic, Salivary Glands 1 (2%) Nose (50) (50) (50) (50) Fibrous Histiocytoma, Metastatic, Skin 1 (2%) Histiocytic Sarcoma 1 (2%) Page 12 NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 450 PPM 900 PPM 1800 PPM ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM - cont Sarcoma, Metastatic, Bone 1 (2%) Pleura (1) Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Eye (49) (48) (49) (49) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Harderian Gland (50) (49) (50) (50) Adenoma 5 (10%) 4 (8%) 5 (10%) 7 (14%) Carcinoma 2 (4%) 1 (2%) 1 (2%) 2 (4%) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (50) (50) (49) (50) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Fibrous Histiocytoma, Metastatic, Skin 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Bone 1 (2%) Renal Tubule, Carcinoma 1 (2%) Ureter (1) Transitional Epithelium, Carcinoma 1 (100%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) *(50) Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) Lymphoma Malignant 1 (2%) 3 (6%) 1 (2%) 2 (4%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 13 NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 450 PPM 900 PPM 1800 PPM ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 45 41 36 45 Total Primary Neoplasms 69 63 52 79 Total Animals with Benign Neoplasms 27 32 29 37 Total Benign Neoplasms 36 39 32 53 Total Animals with Malignant Neoplasms 29 21 16 20 Total Malignant Neoplasms 33 24 20 26 Total Animals with Metastatic Neoplasms 12 8 4 7 Total Metastatic Neoplasm 46 19 5 12 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 14 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------